MK-4280-003: This phase I/II trial is evaluating an immunotherapy combination (MK-4280 and Pembrolizumab) in patients with Hodgkin Lymphoma, Non-Hodgkin Lymphoma or B-Cell LymphomaA Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies

Summary

This is a non-randomised trial, including Part A (dose escalation) and Part B (dose expansion) treatment phases. In Part A, patients will be assigned to receive a standard (200mg) dose of Pembrolizumab followed by varying doses (A, B or C) of MK-4280 by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles. In Part B, patients will be assigned to groups based on their diagnosis. All patients will receive the standard dose (200mg) of Pembrolizumab followed by the recommended phase II dose of MK-4280 by infusion on Day 1 of each 3-week cycle for up to 35 cycles.